EP1809281A2 - Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs - Google Patents

Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs

Info

Publication number
EP1809281A2
EP1809281A2 EP05788787A EP05788787A EP1809281A2 EP 1809281 A2 EP1809281 A2 EP 1809281A2 EP 05788787 A EP05788787 A EP 05788787A EP 05788787 A EP05788787 A EP 05788787A EP 1809281 A2 EP1809281 A2 EP 1809281A2
Authority
EP
European Patent Office
Prior art keywords
dione
dihydroxy
methyl
ethenyl
tetramethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05788787A
Other languages
English (en)
French (fr)
Inventor
Jens Hoffmann
Ulrich Klar
Hubertus Pietsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1809281(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to EP05788787A priority Critical patent/EP1809281A2/de
Publication of EP1809281A2 publication Critical patent/EP1809281A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • Epothilones in the Treatment of Bone Metastasis
  • the present invention relates to the use of Epothilones in the treatment of bone metastases and bone tumors or cancers, more particularly in treating, preventing or alleviating bone metastasis in a cancer patient.
  • the epothilones represent a new class of microtubule stabilizing cytotoxic agents (see Gerth, K. et al., J. Antibiot., 1996, 49, 560-3; or Hoefle et al., Angew. Chem. [Applied Chem.], 1996, 108, 1671-1673). These cytotoxic antimitotic agents, block the mitotic spindle of a proliferating cell by binding to the spindle-peptide tubulin, and thus cause apoptosis (K.-H. Altmann, Curr. Opin. Chem. Biol., 2001 , 5, 424-431).
  • Epothilone A and B as well as some of their synthetic derivatives have recently found interest in connection with the treatment of cancer, and a lot of work has been done on their synthesis (K. Nicolaou et al., Angew. Chem., 1998, 110, 2120-2153) and the synthesis of modified structures.
  • WO 99/07692 disclose Epothilone derivatives, their synthesis and pharmaceutical use.
  • WO 00/66589 deals with the synthesis and pharmaceutical use of Epothilone derivatives having an alkenyl-, alkynyl-, or a cyclic ether containing substituent at the 6(1 Opposition of the macrocyclic ring.
  • WO 00/49021 discloses Epothilone derivatives with a halogen substituent in the 16(3)-position and their synthesis.
  • WO 00/71521 discloses a method for the synthesis of olefinic Epothilones.
  • WO 98/25929 deals with the manufacture of libraries of Epothilone analogs.
  • WO 99/43320 mentions, in a very general manner, the use of Epothilones for the treatment of cancer.
  • WO 03/074053 describes the use of Epothilones and Epothilone analogs in the treatment of brain diseases associated with proliferative processes.
  • WO 04/050089 describes the use of conjugates of Epothilones and Epothilone derivatives (as effectors) with suitable saccharides as saccharide derivatives (as recognition units) in the treatment of proliferative or angiogenesis-associated processes.
  • WO 2004/012735 describes the use of conjugates of Epothilones and Epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) in the treatment of proliferative or angiogenesis-associated processes.
  • WO 03/007924 describes the combination of Epothilones with a bisphosphonate, a platinum compound or a vasculostatic compound as use as combination therapy in the treatment of, inter alia, bone metastasis.
  • the present invention provides the use of an Epothilone in the manufacture of medicaments for use as an inhibitor of bone metastasis and bone tumor growth and is thus useful for the treatment of malignant diseases metastasizing to the bones.
  • the invention also provides a method of inhibiting bone metastasis and bone tumor growth in a patient in need of such treatment, which method comprises the administration to the said patient of an effective amount of an Epothilone.
  • the invention also relates to methods of treating bone metastasis by oral, parental, rectal, or local, preferably inhalational, intravenous, or intraperitoneal, most preferably intravenous administration of an Epothilone.
  • the medicament containing the Epothilone is used to treat, prevent, or alleviate bone metastasis.
  • the bone metastasis results from cancer elsewhere in the body, for example, prostate cancer, breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, ovarian cancer and brain cancer.
  • the medicament is for treating, preventing or alleviating the symptoms of bone metastasis, more particularly in the treatment of bone metastasis in patients with cancer, even more particularly in the treatment of patients with breast and prostate cancer.
  • the medicament may also be used to prevent or alleviate symptoms of pain associated with bone metastases and risk of pathological fractures and hypercalcemia.
  • the medicament containing the Epothilone is used to treat, prevent, or alleviate primary bone tumors or cancers, including benign tumors and malignant tumors such as osteosarcoma, chondrosarcoma, Ewing's tumor, Giant cell tumor of bone, and Chordoma.
  • benign tumors and malignant tumors such as osteosarcoma, chondrosarcoma, Ewing's tumor, Giant cell tumor of bone, and Chordoma.
  • an Epothilone is defined as a cyclic molecule with a 16-membered ring and variable substituents and pharmaceutical activity as a cytostatic agent that binds to tubulin (Asnes et al., Anal. Biochem. 1979, 98, 64-73; Job et al., Cellular Pharmacol. 1993, I (Suppl. I), S7-S10; Lichtner et al., PNAS 2001 , 98, 11743-11748).
  • An Epothilone also includes Epothilone conjugates such as those described in WO 04/050089 and WO 2004/012735 which are herein incorporated by reference.
  • Epothilones are that wherein the Epothilone molecule contains a lactone or a lactame moiety.
  • Preferred Epothilones for use in the present invention are compounds of the general formula:
  • R 1a , R 1b are each independently hydrogen, C- 1 -C 10 alkyl, aryl, aralkyl, or together form a -(CH 2 ) m -group where m is 2 to 5;
  • R 2a , R 2b are each independently hydrogen, C 1 -C 10 alkyl, aryl, aralkyl, or together form a -(CH 2 ) n -group where n is 2 to 5, or are C 2 -C 10 alkenyl or C 2 -Ci 0 alkynyl;
  • R J is hydrogen, C- 1 -C 10 alkyl, aryl, aralkyl
  • R 4a , R 4b are each independently hydrogen, C- 1 -C 10 alkyl, aryl, aralkyl, or together form a -(CH 2 ) P - group where p is 2 to 5;
  • R 5 is hydrogen, C 1 -C 10 alkyl, aryl, aralkyl, CO 2 H, CO 2 alkyl,
  • R 6 , R 7 are each hydrogen, or together form an additional bond, or together form an epoxy function
  • G is O or CH 2 ;
  • X is O, or two groups OR 20 , or a C 2 -Ci O alkylenedioxy group (which may be straight or branched), or H and the group
  • R 8 is hydrogen, d-C-io alkyl, aryl, aralkyl, halogen, CN;
  • R 9 is hydrogen or a protecting group PG X ;
  • R 10 , R 11 are each independently hydrogen, CrC 2O alkyl, aryl, aralkyl, or together with the methylene carbon form a 5- to 7- membered carbocyclic ring;
  • Z is O or H and the group OR 12 ;
  • R 12 is hydrogen or a protecting group PG Z ;
  • R 20 is a Ci-C 20 alkyl group
  • R 21 is hydrogen, or CrC 10 a Ikyl
  • PG X , PG Z is C- 1 -C 20 alkyl, C 4 -C 7 cycloalkyl, which may contain one or more oxygen atoms in the ring, aryl, aralkyl, CrC 2O acyl, aroyl, CrC 20 alkylsulfonyl, arylsulfonyl, W(CrC 20 alkyl)silyl, CN(CrC 20 alkyl) arylsilyl, (CrC 20 alkyl)diarylsilyl, or tri(aralkyl)silyl;
  • terapéuticaally effective amount refers to that amount of a compound of the invention which, when administered to an individual in need thereof, is sufficient to effect treatment, as d efined below, for bone metastasis.
  • the amount which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease and its severity, and the age of the human to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • Treating refers to the treatment of bone metastasis and/or bone tumors or cancers in an individual; and include: (i) preventing the disease from recurring in an individual, in particular, when such individual is in need of further medicamentous treatment after a previous surgical or medicamentous therapy;
  • alkyl refers to straight or branched alkyl groups, e. g., methyl, ethyl, propyl, isopropyl, n-butyl, f-butyl, ⁇ -pentyl, neopentyl, heptyl, or decyl.
  • Alkyl groups can be perfluorated or substituted by one to five substituents selected from the group consisting of halogen, hydroxy, d-C 4 alkoxy, or C 6 -Ci 2 aryl (which can be substituted by one to three halogen atoms).
  • alkenyl refers to a straight or branched chain monovalent or divalent radical, containing at least one double bond and having from two to ten carbon atoms, e.g., ethenyl, prop-2-en-1-yl, but-1 -enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like.
  • alkynyl refers to a substituted or unsubstituted straight or branched chain monovalent or divalent radical, containing at least one triple bond and having from two to ten carbon atoms, e.g., ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-3-ynyl, and the like.
  • Alkenyl and alkenyl groups can be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, -CO 2 H, - CO 2 Alkyl, -NH 2 , -NO 2 , -N 3 , -CN, C 1 -C 20 acyl, or C r C 20 acyloxy.
  • aryl refers to an aromatic carbocyclic or heterocyclic moiety containing five to 14 ring atoms, e.g., phenyl, naphth/l, furyl, thienyl, pyridyl, pyrazolyl, pyrimidinyl, oxazolyl, pyridazinyl, pyrazinyl, chinolyl, or thiazolyl.
  • Aryl groups can be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, -CO 2 H, -CO 2 Alkyl, -NH 2 , Alkyl-NH 2 , CrC 20 alkyl-thiolanyl, -NO 2 , -N 3 , -CN, CrC 2 O alkyl.
  • the heteroatoms can be oxidized, if this does not cause a loss of aromatic character, e. g., a pyridine moiety can be oxidized to give a pyridine N- oxide.
  • aralkyl refers to a group which can contain up to 14 atoms in the aryl ring (preferred five to ten) and one to eight carbon atoms in the alkyl chain (preferred one to four), e.g., benzyl, phenylethyl, naphthylmethyl, naphthylethyl, furylmethyl, thienylethyl, or pyridylpropyl.
  • the rings can be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, -CO 2 H, -CO 2 Alkyl, -NH 2 , -NO 2 , -N 3 , -CN, C r C 20 alkyl, CrC 20 acyl, or CrC 20 acyloxy.
  • the protecting groups PG can be alkyl- and/or aryl-substituted silyl moieties, Ci- C 20 alkyi, C 4 -C 7 cycloalkyl, which may contain an oxygen atom in the ring, aryU aralkyl, CrC 20 acyl, aroyl, alkyl- or arylsulfonyl.
  • Groups which can be easily be removed from the molecule are preferred, e.g., methoxymethyl, methoxyethyl , polyethylene glycol, ethoxyethyl, tetrahydropyranyl, tetrahydrofuranyl, trimethylsilyl, triethylsilyl, /-butyldimethylsilyl, tribenzylsilyl, triisopropylsilyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, as well as alkylsulfonyl or arylsulfonyl .
  • acyl groups are formyl, acetyl, propionyl, pivaloyl, butyryl, or benzoyl . which all can be substituted by one or more amino and/or hydroxy moieties.
  • R 2a , R 2b are each independently hydrogen, C 2 -Ci O alkenyl or C 2 -Ci 0 alkynyl; R 6 , R 7 form an epoxy function or together form an additional bond; W is a 2-Methyl-benzothiazol-5-yl radical or a 2-Methyl-benzoxazol-5-yl radical or a Quinoline-7-yl radical.
  • a preferred subgroup is compounds selected from the following: (4S,7R,8S,9S,13E/Z,16S)-4,8-dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;
  • a preferred subgroup is compounds selected from the following: (4S,7R,8S ! 9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4- thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyI-7-ethyl-cyclohexadec-13-ene-2,6- dione;
  • a preferred subgroup is compounds selected from the following: (4S J 7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- oxa- ⁇ . ⁇ .i S-tetramethyl ⁇ prop ⁇ -in-i-yO-cyclohexadec-IS-ene ⁇ . ⁇ -dione;
  • the compounds can be formulated by methods known in the art.
  • Compositions for the oral, rectal, parenteral or local application can be prepared in the form of tablets, capsules, granulates, suppositories, implantates, sterile injectable aqueous or oily solutions, suspensions or emulsions, aerosols, salves, creams, or gels, retard preparations or retard implantates.
  • the compounds may also be administered by implantable dosing systems.
  • the pharmaceutical active compound(s) can thus be mixed with adjuvants known in the art, such as gum arabic, talcum, starch, mannitol, methyl cellulose, lactose, surfactants such as tweensd ⁇ or myrj®, magnesium stearate, aqueous or non-aqueous carriers, paraffin derivatives, wetting agents, dispersing agents, emulsifiers, preservatives, and flavors.
  • adjuvants known in the art, such as gum arabic, talcum, starch, mannitol, methyl cellulose, lactose, surfactants such as tweensd ⁇ or myrj®, magnesium stearate, aqueous or non-aqueous carriers, paraffin derivatives, wetting agents, dispersing agents, emulsifiers, preservatives, and flavors.
  • the compounds can be used in the form of their clathrates of o, ⁇ -, or ⁇ - cyclodextrin or of substituted ⁇ -, ⁇ -, or ⁇ -cyclodextrines, or in the form of a liposomal composition, in particular a liposomal composition comprising a polyethyleneglycol(PEG)-derivatized lipid.
  • the invention also relates to pharmaceutical compositions containing one or more of the pharmaceutically active compounds listed above, and their use for the treatment and in the methods in accordance with the present invention.
  • one dose unit of these compositions contains about 0.01-100 mg of the pharmaceutically active compound(s).
  • the dosage for the use according to the invention for a human is about 0.01-100 mg per day; a preferred dosage is about 0.02-70 mg per day; a more preferred dosage is about 0.04-40 mg per day.
  • SREs skeletal-related events
  • mice Four days before tumor cells implantation, the baseline bone structure of the mice was determined by X-ray. 30 NMRI nude mice received 500,000 of MDA-
  • MB 231 breast cancer tumor cells intracardially (Day 0).
  • the tumor cells metastasized to the bones and the growth of the tumor in the bones lead to bone destruction.
  • 10 of the 29 animals were treated with the Test Compound (10 mg/kg, Lv.).
  • the size and number of bone metastases were monitored 4 days before tumor cell implantation
  • mice Preparation of the Animals (anaesthesia, fixation)
  • the mice underwent an anaesthesia with a mixture of Rompun ( Rompun 2% Bayer) diluted with sodium chloride solution( Braun) by 1 :10 and Ketavet ( Pharmacia GmbH 100mg/ ml), diluted by 1 :5 with isotonic sodium chloride solution.
  • Rompun Rompun 2% Bayer
  • Ketavet Pharmacia GmbH 100mg/ ml
  • 1 ml sterile syringes Codan Medical
  • cannula Braun Sterican, size 18
  • mice were attached to a 1 mm strong acrylic glass and additionally taped with a self-adhesive tape (sticky side facing the animal).
  • the acrylic glass served as surface on which the animals underwent the X-ray.
  • the standard setting of 35kV and 40OmAs was adjusted.
  • the setting was chosen in such a way to allow a good contrasting of the entire skeletal system and visibility of finest changes/aberrations of the bone structure and morphology.
  • the resolution of the systems lies at 0,27 ⁇ m.
  • the module "Zoomed Modus” was chosen for the detector and the ROIs 2-3 were selected in accordance with the previously selected positioning of the mouse.
  • the regulator Image High was adjusted to 2000.
  • the actual measurements were started as soon as the Offset measurings and the reference measurings had been performed.
  • the flexible table was brought into position (80 mm) and was advanced at a speed of 25,9 mm/sec.
  • the final position of the table was chosen in such a way that the entire body of the mouse could be X-rayed all at once during the examination.
  • the reference measuring was subtracted from each gained Image and was stored as a DICOM-fiie or as a BMP-file.
  • Results shown in Figure 1 show that the Test Compound inhibited bone metastasis in the in vivo model and that a prolongation of life time was observed. In fact, the size of the bone metastases were reduced after just 12 days following a single treatment and Mean Survival Time was improved.
  • treatment with the Test Compound resulted in a 5.9 mm 2 Mean Tumor Area compared to 14.0 mm 2 without treatment.
  • the overall Mean Survival Time rose from 23.4 days without treatment to 31.6 days following a single application of the Test Compound in the treatment group.
  • Figure 1 visualises the efficacy in the bone metastasis model.
  • the baseline bone structure of the mice was determined by X-ray (Animal #01 , left).
  • MDA-MB 231 breast cancer tumor cells were implanted intracardially into nude mice on Day 0 (i.e. four days after baseline). Treatment was started on Day 10 when first signs of bone metastasis were observed.
  • the same untreated animal whose survival time of 23 days is close to the mean survival time (23.4 days) of the untreated control group, has developed severe bone metastasis on Day 22 (see white arrows, middle).
  • Animal #22 represents a typical member of the treatment group whose survival time of 30 days is close to the mean survival time (31.6 days) in the treatment group. Size and amount of bone metastasis are reduced.
  • the Test Compound was given in the indicated dose. The size of the bone metastases after Day 22 with and without treatment is shown.
  • Results are shown in Table 2: The mean number of bone metastases is significantly reduced from 21.2 per animal in the untreated control group (Group 1) to 0.7 per animal in the group treated with the Test Compound (Group 2). The mean size of bone metastases is significantly reduced from 8.1 mm 2 per animal in Group 1 to 0.1 mm 2 per animal in Group 2.
  • the number of animals which developed tumors at the tumor cell injection site is reduced from 5 aminals in Group 1 to 0 animals in Group 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP05788787A 2004-09-24 2005-09-22 Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs Withdrawn EP1809281A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05788787A EP1809281A2 (de) 2004-09-24 2005-09-22 Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (de) 2004-09-24 2004-09-24 Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
EP05788787A EP1809281A2 (de) 2004-09-24 2005-09-22 Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs
PCT/EP2005/010400 WO2006032537A2 (en) 2004-09-24 2005-09-22 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
EP1809281A2 true EP1809281A2 (de) 2007-07-25

Family

ID=34928830

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04090377A Withdrawn EP1640004A1 (de) 2004-09-24 2004-09-24 Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
EP05788787A Withdrawn EP1809281A2 (de) 2004-09-24 2005-09-22 Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04090377A Withdrawn EP1640004A1 (de) 2004-09-24 2004-09-24 Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs

Country Status (21)

Country Link
EP (2) EP1640004A1 (de)
JP (1) JP2008514569A (de)
KR (1) KR20070054214A (de)
CN (1) CN101065126A (de)
AR (1) AR051035A1 (de)
AU (1) AU2005287477A1 (de)
BR (1) BRPI0516080A (de)
CA (1) CA2580215A1 (de)
CR (1) CR9064A (de)
EC (1) ECSP077390A (de)
GT (1) GT200500267A (de)
IL (1) IL181785A0 (de)
MX (1) MX2007003503A (de)
NO (1) NO20072099L (de)
PA (1) PA8646201A1 (de)
PE (1) PE20060695A1 (de)
RU (1) RU2007115162A (de)
TW (1) TW200626150A (de)
UY (1) UY29136A1 (de)
WO (1) WO2006032537A2 (de)
ZA (1) ZA200703306B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (de) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Einsatz von Epothilonen bei der Behandlung von Osteoporose und ähnlichen Krankheiten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
PT1140944E (pt) * 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
EP1503756B1 (de) * 2002-05-01 2009-08-12 Novartis AG Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
JP2006510626A (ja) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (de) * 2003-05-09 2004-11-10 Schering AG Knochengewebegerichtetes Radiopharmaceuticum und Tubulin-interagierende Verbindung kombinatorischer Radiotherapie
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006032537A2 *

Also Published As

Publication number Publication date
AR051035A1 (es) 2006-12-13
KR20070054214A (ko) 2007-05-28
IL181785A0 (en) 2007-07-04
WO2006032537A2 (en) 2006-03-30
MX2007003503A (es) 2007-08-17
CN101065126A (zh) 2007-10-31
BRPI0516080A (pt) 2008-08-19
ECSP077390A (es) 2007-05-30
AU2005287477A1 (en) 2006-03-30
TW200626150A (en) 2006-08-01
ZA200703306B (en) 2010-06-30
CA2580215A1 (en) 2006-03-30
PE20060695A1 (es) 2006-08-03
EP1640004A1 (de) 2006-03-29
WO2006032537A3 (en) 2006-05-04
JP2008514569A (ja) 2008-05-08
GT200500267A (es) 2006-06-06
RU2007115162A (ru) 2008-11-20
NO20072099L (no) 2007-04-23
PA8646201A1 (es) 2006-11-09
UY29136A1 (es) 2006-04-28
CR9064A (es) 2007-10-01

Similar Documents

Publication Publication Date Title
RU2351330C2 (ru) Применение эпотилонов в лечении заболеваний головного мозга, ассоциированных с пролиферативными процессами
ES3053660T3 (en) Pharmaceutical combination comprising ponesimod and its use in the treatment of multiple sclerosis
JP2002504511A5 (de)
JP2003531821A5 (de)
AU2010308306A1 (en) Combination cancer therapy with HSP90 inhibitory compounds
CA2193751A1 (en) Treatment and prophylaxis of osteoporosis
JP2005527576A (ja) エポチロン化合物の経口投与
JPH08509486A (ja) アテローム性動脈硬化症および食事障害の治療についてのチアゾリジンジオンの使用
JP2005528414A (ja) 肝臓癌および他の癌疾患の処置用エポチロン誘導体
CN105263501A (zh) 具有抗转移活性的糖-类似物含磷杂环
EP1809281A2 (de) Verwendung von epothilonen zur behandlung von knochenmetastasen und knochentumoren oder knochenkrebs
US20060069136A1 (en) Use of Epothilones in the treatment of bone metastasis
WO2008068043A1 (en) Use of epothilones in the treatment of osteoporosis and related diseases
US20140024687A1 (en) Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists
JP2004525168A (ja) 腫瘍の成長を抑制もしくは減少するための単独または他の治療薬との組合わせでのチアゾリジンジオン
JP2007530567A (ja) エポチロン及びカルボプラチンを用いる併用療法
JPH11335298A (ja) 白血病治療剤
MXPA06010921A (en) Combination therapies with epothilones and carboplatin
ZA200607806B (en) Combination therapies with epothilones and carboplatin
JP2001213783A (ja) 動物用治療剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070312

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20090609

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090922